osimertinib
astrazeneca
['adaura', 'osimertinib', 'nsclc', 'sclc', 'aura ,(-laura)']
adjuvant osimertinib in patients after resection of early nsclc with egfr mutations. update of the adaura trial. dfs benefits confirmed. 9% qt prolongation. updated overall suvival, a critical endpoint in the curative setting, was not presented. #esmo22 
Medical Oncologist - Lung cancer & thymic tumors. Head of Clinical Research @GustaveRoussy - Head of Scientific Chairs Council @EORTC. Tweets are my own.